S&P 500   3,377.36 (+0.50%)
DOW   28,056.82 (+0.95%)
QQQ   270.22 (-0.03%)
AAPL   446.06 (-1.08%)
MSFT   207.45 (-0.38%)
FB   265.28 (+0.87%)
GOOGL   1,509.66 (+0.86%)
AMZN   3,152.66 (+0.14%)
NVDA   442.32 (-0.96%)
CGC   17.70 (-1.28%)
BABA   251.72 (+1.45%)
TSLA   1,412.49 (-0.43%)
GE   6.81 (+1.95%)
MU   48.84 (-0.63%)
AMD   79.05 (-3.88%)
T   30.36 (+0.53%)
F   7.28 (+2.68%)
ACB   10.10 (-1.17%)
GILD   68.30 (-0.31%)
NFLX   476.08 (-1.51%)
DIS   131.26 (+1.92%)
BAC   27.40 (+3.16%)
BA   185.20 (+3.23%)
S&P 500   3,377.36 (+0.50%)
DOW   28,056.82 (+0.95%)
QQQ   270.22 (-0.03%)
AAPL   446.06 (-1.08%)
MSFT   207.45 (-0.38%)
FB   265.28 (+0.87%)
GOOGL   1,509.66 (+0.86%)
AMZN   3,152.66 (+0.14%)
NVDA   442.32 (-0.96%)
CGC   17.70 (-1.28%)
BABA   251.72 (+1.45%)
TSLA   1,412.49 (-0.43%)
GE   6.81 (+1.95%)
MU   48.84 (-0.63%)
AMD   79.05 (-3.88%)
T   30.36 (+0.53%)
F   7.28 (+2.68%)
ACB   10.10 (-1.17%)
GILD   68.30 (-0.31%)
NFLX   476.08 (-1.51%)
DIS   131.26 (+1.92%)
BAC   27.40 (+3.16%)
BA   185.20 (+3.23%)
S&P 500   3,377.36 (+0.50%)
DOW   28,056.82 (+0.95%)
QQQ   270.22 (-0.03%)
AAPL   446.06 (-1.08%)
MSFT   207.45 (-0.38%)
FB   265.28 (+0.87%)
GOOGL   1,509.66 (+0.86%)
AMZN   3,152.66 (+0.14%)
NVDA   442.32 (-0.96%)
CGC   17.70 (-1.28%)
BABA   251.72 (+1.45%)
TSLA   1,412.49 (-0.43%)
GE   6.81 (+1.95%)
MU   48.84 (-0.63%)
AMD   79.05 (-3.88%)
T   30.36 (+0.53%)
F   7.28 (+2.68%)
ACB   10.10 (-1.17%)
GILD   68.30 (-0.31%)
NFLX   476.08 (-1.51%)
DIS   131.26 (+1.92%)
BAC   27.40 (+3.16%)
BA   185.20 (+3.23%)
S&P 500   3,377.36 (+0.50%)
DOW   28,056.82 (+0.95%)
QQQ   270.22 (-0.03%)
AAPL   446.06 (-1.08%)
MSFT   207.45 (-0.38%)
FB   265.28 (+0.87%)
GOOGL   1,509.66 (+0.86%)
AMZN   3,152.66 (+0.14%)
NVDA   442.32 (-0.96%)
CGC   17.70 (-1.28%)
BABA   251.72 (+1.45%)
TSLA   1,412.49 (-0.43%)
GE   6.81 (+1.95%)
MU   48.84 (-0.63%)
AMD   79.05 (-3.88%)
T   30.36 (+0.53%)
F   7.28 (+2.68%)
ACB   10.10 (-1.17%)
GILD   68.30 (-0.31%)
NFLX   476.08 (-1.51%)
DIS   131.26 (+1.92%)
BAC   27.40 (+3.16%)
BA   185.20 (+3.23%)
Log in

OTCMKTS:CYDYCytoDyn Stock Price, Forecast & News

$4.81
+0.02 (+0.42 %)
(As of 08/11/2020 12:47 PM ET)
Add
Compare
Today's Range
$4.50
Now: $4.81
$4.89
50-Day Range
$3.68
MA: $5.43
$8.77
52-Week Range
$0.26
Now: $4.81
$10.01
Volume4.13 million shs
Average Volume7.07 million shs
Market Capitalization$2.72 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.66
CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. The company has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. CytoDyn Inc. is based in Vancouver, Washington.
Read More
CytoDyn logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.85 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CYDY
Previous SymbolNASDAQ:CYDY
CUSIP23283M101
Phone360-980-8524

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.03) per share

Profitability

Net Income$-56,190,000.00

Miscellaneous

Employees6
Market Cap$2.72 billion
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable
$4.81
+0.02 (+0.42 %)
(As of 08/11/2020 12:47 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CYDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CYDY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CytoDyn (OTCMKTS:CYDY) Frequently Asked Questions

How has CytoDyn's stock been impacted by COVID-19 (Coronavirus)?

CytoDyn's stock was trading at $1.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CYDY shares have increased by 367.0% and is now trading at $4.81.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of CytoDyn?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytoDyn in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for CytoDyn
.

When is CytoDyn's next earnings date?

CytoDyn is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for CytoDyn
.

How were CytoDyn's earnings last quarter?

CytoDyn Inc (OTCMKTS:CYDY) released its earnings results on Tuesday, October, 9th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.01.
View CytoDyn's earnings history
.

What price target have analysts set for CYDY?

1 analysts have issued 1 year price targets for CytoDyn's stock. Their forecasts range from $4.00 to $4.00. On average, they expect CytoDyn's share price to reach $4.00 in the next year. This suggests that the stock has a possible downside of 16.8%.
View analysts' price targets for CytoDyn
.

Has CytoDyn been receiving favorable news coverage?

Media stories about CYDY stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CytoDyn earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about CytoDyn
.

Are investors shorting CytoDyn?

CytoDyn saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 6,311,200 shares, an increase of 15.8% from the January 31st total of 5,451,900 shares. Based on an average daily volume of 12,749,800 shares, the days-to-cover ratio is presently 0.5 days.
View CytoDyn's Short Interest
.

Who are some of CytoDyn's key competitors?

What other stocks do shareholders of CytoDyn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), NVIDIA (NVDA), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Micron Technology (MU), Advanced Micro Devices (AMD), Moderna (MRNA), Tesla (TSLA) and Heat Biologics (HTBX).

Who are CytoDyn's key executives?

CytoDyn's management team includes the following people:
  • Dr. Nader Z. Pourhassan, CEO, Pres & Director (Age 56)
  • Mr. Michael D. Mulholland, CFO, Treasurer & Corp. Sec. (Age 67)
  • Dr. Denis R. Burger, Scientific Consultant (Age 75)
  • Dr. Richard G. Pestell M.B.A., M.D., MBA. M.D., Ph.D., Vice Chairman & Chief Medical Officer
  • Dr. Nitya G. Ray, Chief Technology Officer & Head of Process Sciences, Manufacturing and Supply Chain (Age 66)

What is CytoDyn's stock symbol?

CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."

How do I buy shares of CytoDyn?

Shares of CYDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CytoDyn's stock price today?

One share of CYDY stock can currently be purchased for approximately $4.81.

How big of a company is CytoDyn?

CytoDyn has a market capitalization of $2.72 billion. The biotechnology company earns $-56,190,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. CytoDyn employs 6 workers across the globe.

What is CytoDyn's official website?

The official website for CytoDyn is www.cytodyn.com.

How can I contact CytoDyn?

CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company can be reached via phone at 360-980-8524 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.